Evidence map›Paper›PMID 38782821›Full record

ReviewPsychopharmacology2024

Psychedelic-assisted psychotherapy: where is the psychotherapy research?

Jacob S Aday, David Horton, Gisele Fernandes-Osterhold, Aoife O'Donovan, Ellen R Bradley, Raymond C Rosen, Joshua D Woolley

Abstract readReview
PubMed Publisher
In one paragraph

Review in Psychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Psychedelic therapy and cultural humility.Translational psychiatry · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Addressing blinding in classic psychedelic studies with innovative active placebos.The international journal of neuropsychopharmacology · 2025
    Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jacob S AdayDepartment of Anesthesiology, University of Michigan, Ann Arbor, MI, USA. adayj@med.umich.edu.ORCID http://orcid.org/0000-0003-0578-8530
David HortonDepartment of Family Medicine and Community Health, University of Wisconsin, Madison, Madison, WI, USA.
Gisele Fernandes-OsterholdDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
Aoife O'DonovanDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
Ellen R BradleyDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
Raymond C RosenDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.
Joshua D WoolleyDepartment of Psychiatry and Behavioral Sciences, University of California, San Francisco, CA, USA.

Funding

TRAINING OF ARTHRITIS RESEARCH SCIENTISTST32AR007080 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Jason Knight · 1986 to 2026
$6.3M
NIAMS NIH HHS T32 AR007080
6 · The paper itself

Abstract

rationalePsychedelic-assisted psychotherapy (PAP) has emerged as a potential treatment for a variety of mental health conditions, including substance use disorders and depression. Current models of PAP emphasize the importance of psychotherapeutic support before, during, and after ingestion of a psychedelic to maximize safety and clinical benefit. Despite this ubiquitous assumption, there has been surprisingly little empirical investigation of the "psychotherapy" in PAP, leaving critical questions about the necessary and sufficient components of PAP unanswered.

objectivesAs clinical trials for psychedelic compounds continue the transition from safety- and feasibility-testing to evaluating efficacy, the role of the accompanying psychotherapy must be better understood to enhance scientific understanding of the mechanisms underlying therapeutic change, optimize clinical outcomes, and inform cost-effectiveness.

resultsThe present paper first reviews the current status of psychotherapy in the PAP literature, starting with recent debates regarding "psychotherapy" versus "psychological support" and then overviewing published clinical trial psychotherapy models and putative models informed by theory. We then delineate lessons that PAP researchers can leverage from traditional psychotherapy research regarding standardizing treatments (e.g., publish treatment manuals, establish eligibility criteria for providers), identifying mechanisms of change (e.g., measure established mechanisms in psychotherapy), and optimizing clinical trial designs (e.g., consider dismantling studies, comparative efficacy trials, and cross-lagged panel designs). Throughout this review, the need for increased research into the psychotherapeutic components of treatment in PAP is underscored.

conclusionsPAP is a distinct, integrative, and transdisciplinary intervention. Future research designs should consider transdisciplinary research methodologies to identify best practices and inform federal guidelines for PAP administration.

Indexed as

HallucinogensMental DisordersPsychotherapyHumansSubstance-Related DisordersHallucinogensPsilocybinPsychedelicPsychedelic-assisted psychotherapyPsychotherapyPsychotherapy modelsReview

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.